Product Information
ATELVIA DR 35 MG TABLET is a brand product labeled by Allergan, Inc., priced at $63.8079 per EA under NDC 00430097903. Its NADAC has been published 410 times since Nov 28, 2013.
FDA first approved this application on Oct 8, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the risedronate sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30.1; 4.9 mg/1; mg/1
Manufacturer
Allergan, Inc.NDC
00430097903
Classification
Brand
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RISEDRONATE SODIUM HEMIPENTAHYDRATE; RISEDRONATE SODIUM MONOHYDRATEApproval Type
New Drug (NDA)
FDA Application
NDA022560FDA Approved
10/8/2010
TE Code
AB
On Market Since
12/1/2010
Pharmacological Classes
Price Statistics
The NADAC for ATELVIA DR 35 MG TABLET has been published 410 times since Nov 28, 2013, and over the history we have for it it has risen 81.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $63.8079 per EA |
|---|---|
| All-time high | $64.0500 (Jul 15, 2026) |
| All-time low | $35.0716 (Nov 28, 2013) |
| 52-week high | $64.0500 |
| 52-week low | $63.2246 |
| Median price | $56.0674 |
| Average price | $55.0777 |
| Largest weekly change | +14.9% (Jan 14, 2015) |
| Weeks tracked | 410 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 52% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
risedronate sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATELVIA DR 35 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATELVIA DR 35 MG TABLET, manufactured by Allergan, Inc., is $63.8079 per EA (NDC 00430097903), effective Sep 30, 2026.
How has the price of ATELVIA DR 35 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATELVIA DR 35 MG TABLET has risen 81.9%. It has been tracked across 410 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ATELVIA DR 35 MG TABLET?
Since Nov 28, 2013, the NADAC for ATELVIA DR 35 MG TABLET has ranged from a low of $35.0716 (Nov 28, 2013) to a high of $64.0500 (Jul 15, 2026), with a median of $56.0674 per EA.
Are there cheaper alternatives to ATELVIA DR 35 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISEDRONATE SOD DR 35 MG TAB, is $30.6772 per EA — about 52% below ATELVIA DR 35 MG TABLET.
Who manufactures ATELVIA DR 35 MG TABLET?
ATELVIA DR 35 MG TABLET (NDC 00430097903) is labeled by Allergan, Inc., and CMS classifies it as a brand product.